Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)

• Published in: Journal of clinical pharmacology Vol. 53; no. 7; p. 721
• Main Authors: Chen, Xuejun, Williams, William V, Sandor, Victor, Yeleswaram, Swamy
• Format: Journal Article
• Language: English
• Published: England 01.07.2013
• Subjects: Aged; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Janus Kinases - antagonists & inhibitors; Male; Models, Biological; Polycythemia Vera - drug therapy; Polycythemia Vera - metabolism; Primary Myelofibrosis - drug therapy; Primary Myelofibrosis - metabolism; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - administration & dosage; Pyrazoles - pharmacokinetics; Randomized Controlled Trials as Topic; Thrombocythemia, Essential - drug therapy; Thrombocythemia, Essential - metabolism

Ruxolitinib is a selective inhibitor of Janus kinase 1 and 2, which is approved to treat intermediate or high-risk myelofibrosis. The population pharmacokinetics for ruxolitinib were characterized by a modeling dataset of 272 subjects from a Phase 2 and a Phase 3 study and validated by an external v...